Rivus Pharmaceuticals Announces Leadership Transition, Appointment of Jayson Dallas, M.D., As CEO

- Allen Cunningham appointed Chief Operating Officer, guiding execution of the company's clinical programs for HU6 to treat cardiometabolic disease","Rivus Pharmaceuticals Inc., a clinical-stage biopharmaceutical company dedicated to improving cardiometabolic health, today announced the appointment of Jayson Dallas, M.D., executive chairman for Rivus Pharmaceuticals, as Chief Executive Officer. Allen Cunningham, who previously held the post, will transition to the role of Chief Operating Officer. In this role, Allen will continue to drive day-to-day operations and clinical development of the company's lead candidate HU6, a first-in-class controlled metabolic accelerator designed to treat serious cardiometabolic diseases.